We're launching our first lifespan study, in collaboration with Ichor Therapeutics, on the synthetic pineal peptide epitalon.
18-month-old C57BL/6 mice (50 male and 50 female) will be divided into treatment (n=50) and control (n=50) groups, for a total study size of n=100. Animals will be monitored daily and housed in a specific pathogen free vivarium using 12-hour light/dark schedule with chlorinated RO water and standard mouse chow provided ad lib.
Mice will receive 1 ug epitalon (Ala-Glu-Asp-Gly peptide) or sterile saline (control) subcutaneous injection for 5 consecutive days per month every month. Treatment regime will be blinded and randomized.
The primary study endpoint is median lifespan; secondary endpoints include maximum lifespan, motor fitness, and tumor burden. Mouse weights will be recorded bi-weekly. Food consumption will be measured on a per-cage basis. Locomotor fitness will be assessed every 6 months and will include the horizontal bar test, grip strength, open field test, and roto-rod test. Upon death, animals will undergo necropsy and organ weighing to test for tumor burden and other diseases of aging.